Erythema multiforme: distinguishing hypersensitivity reactions, drug allergy, or herpes simplex infection

Abstract

Cutaneous reactions present a diagnostic challenge, mainly when multiple factors, such as infections, medications, and environmental triggers, contribute to the clinical picture. Erythema multiforme (EM) is an acute, self-limiting mucocutaneous disorder that is most commonly triggered by herpes simplex virus (HSV) but can also be associated with drug-induced hypersensitivity reactions. Diagnosing EM becomes even more complex in patients taking photosensitizing medications, such as doxycycline, which can cause phototoxic or photoallergic reactions. Differentiating between drug-induced and infection-associated EM, as well as distinguishing it from more severe conditions like Stevens-Johnson syndrome (SJS), is crucial for appropriate management. This case report presents a case of a 57-year-old Caucasian female with a history of penicillin allergy who developed a phototoxic reaction to doxycycline following sun exposure. She was treated with silver sulfadiazine for her skin lesions but subsequently developed EM, with target-like lesions predominantly on the legs and a concurrent herpes simplex labialis infection. Laboratory findings were unremarkable, and there was no mucosal involvement. Given the suspected drug-induced nature of the reaction and the presence of HSV, a cautious approach was taken. Treatment with oral prednisone led to the resolution of symptoms without recurrence. Patch testing for doxycycline and silver sulfadiazine was omitted due to the risk of severe cutaneous adverse drug reactions (SCARs) and their non-essential status. Instead, penicillin testing was prioritized due to its clinical importance, and the patient successfully passed the oral amoxicillin challenge. This case highlights the diagnostic challenges of differentiating between drug-induced, infection-triggered, and photosensitivity-related cutaneous reactions. A careful evaluation of medication history, infection status, and clinical presentation is essential to guide the management of this condition.

Keywords

Hypersensitivity / drug allergy / drug phototoxicity / erythema multiforme

References

[1] Nigen S, Knowles SR, Shear NH. Drug eruptions: approaching the diagnosis of drug-induced skin diseases. J Drugs Dermatol. 2003; 2: 278-99.

[2] Svensson CK, Cowen EW, Gaspari AA. Cutaneous drug reactions. Pharmacol Rev. 2001; 53: 357-79.

[3] Soares A, Sokumbi O. Recent Updates in the Treatment of Erythema Multiforme. Medicina (Kaunas). 2021; 57: 921.

[4] Samim F, Auluck A, Zed C, Williams PM. Erythema multiforme: a review of epidemiology, pathogenesis, clinical features, and treatment. Dent Clin North Am. 2013; 57: 583-96.

[5] Watanabe R, Watanabe H, Sotozono C, Kokaze A, Iijima M. Critical factors differentiating erythema multiforme majus from Stevens-Johnson syndrome (SJS)/toxic epidermal necrolysis (TEN). Eur J Dermatol. 2011; 21: 889-94.

[6] Kutlubay Z, Sevim A, Engin B, Tüzün Y. Photodermatoses, including phototoxic and photoallergic reactions (internal and external). Clin Dermatol. 2014; 32: 73-9.

[7] Monteiro AF, Rato M, Martins C. Drug-induced photosensitivity: Photoallergic and phototoxic reactions. Clin Dermatol. 2016; 34: 571-81.

[8] Kazmierowski JA, Wuepper KD. Erythema multiforme: clinical spectrum and immunopathogenesis. Springer Semin Immunopathol. 1981; 4: 45-53.

[9] Brockow K, Ardern-Jones MR, Mockenhaupt M, Aberer W, Barbaud A, Caubet J, et al. EAACI position paper on how to classify cutaneous manifestations of drug hypersensitivity. Allergy. 2019; 74: 14-27.

[10] Rodríguez-Pazos L, Gómez-Bernal S, Montero I, Rodríguez-Granados M, Toribio J. Erythema multiforme photoinduced by paroxetine and herpes simplex virus. Photodermatol Photoimmunol Photomed. 2011; 27: 219-21.

[11] Huff C, Weston WL. The photodistribution of erythema multiforme. Arch Dermatol. 1980; 116: 477.

[12] Fitzpatrick JE, Thompson PB, Aeling JL, Huff C. Photosensitive recurrent erythema multiforme. J Am Acad Dermatol. 1983; 9: 419-23.

[13] Sethy M, Padhan P, Abirami C, Maikap D. Rowell’s Syndrome: A Case Report and Literature Overview. Indian Dermatol Online J. 2021; 12: 608-10.

[14] Adelman MJ, Messenger G, Farshchian M, Moossavi M. Toxic epidermal necrolysis induced by doxycycline. Int J Dermatol. 2021; 60: e398-400.

[15] Lockhart SP, Rushworth A, Azmy AA, Raine PA. Topical silver sulphadiazine: side effects and urinary excretion. Burns Incl Therm Inj. 1983; 10: 9-12.

[16] Woodruff CM, Botto N. The Role of Patch Testing in Evaluating Delayed Hypersensitivity Reactions to Medications. Clin Rev Allergy Immunol. 2022; 62: 548-61.

[17] Novack DE, Braskett M, Worswick SD, Adler BL. Drug patch testing in Stevens-Johnson syndrome and toxic epidermal necrolysis: A systematic review. Ann Allergy Asthma Immunol. 2023; 130: 628-36.

[18] Degreef H, Dooms-Goossens A. Patch testing with silver sulfadiazine cream. Contact Dermatitis. 1985; 12: 33-7.

[19] Binet O, Bruley C, Robin J. Photo-patch testing and patch testing with silver sulfadiazine cream. Photodermatol. 1987; 4: 102-3.

[20] Fraser-Moodie A. Sensitivity to silver in a patient treated with silver sulphadiazine (Flamazine). Burns. 1992; 18: 74-5.

[21] Sawada Y. Adverse reaction to sulphonamides in a burned patient——a case report. Burns Incl Therm Inj. 1985; 12: 127-31.

[22] Hamilton LA, Guarascio AJ. Tetracycline Allergy. Pharmacy (Basel). 2019; 7: 104.

[23] Parish LC, Witkowski JA. Pulsating fixed drug eruption due to tetracycline. Acta Derm Venereol. 1978; 58: 545-7.

[24] Honari G. Photoallergy. Rev Environ Health. 2014; 29: 233-42.

[25] Drucker AM, Rosen CF. Drug-induced photosensitivity: culprit drugs, management and prevention. Drug Saf. 2011; 34: 821-37.

[26] Layton AM, Cunliffe WJ. Phototoxic eruptions due to doxycycline——a dose-related phenomenon. Clin Exp Dermatol. 1993; 18: 425-7.

[27] Goetze S, Hiernickel C, Elsner P. Phototoxicity of Doxycycline: A Systematic Review on Clinical Manifestations, Frequency, Cofactors, and Prevention. Skin Pharmacol Physiol. 2017; 30: 76-80.

[28] Ramien ML. Reactive infectious mucocutaneous eruption: Mycoplasma pneumoniae-induced rash and mucositis and other parainfectious eruptions. Clin Exp Dermatol. 2021; 46: 420-9.

[29] Roca B. Mycoplasma infections. Rev Clin Esp. 2006; 206: 239-42. Spanish.

[30] Aurelian L, Ono F, Burnett J. Herpes simplex virus (HSV)-associated erythema multiforme (HAEM): a viral disease with an autoimmune component. Dermatol Online J. 2003; 9: 1.

[31] Ono F, Sharma BK, Smith CC, Burnett JW, Aurelian L. CD34+ cells in the peripheral blood transport herpes simplex virus DNA fragments to the skin of patients with erythema multiforme (HAEM). J Invest Dermatol. 2005; 124: 1215-24.

[32] Demoly P, Adkinson NF, Brockow K, Castells M, Chiriac AM, Greenberger PA, et al. International Consensus on drug allergy. Allergy. 2014; 69: 420-37.

[33] Sassolas B, Haddad C, Mockenhaupt M, Dunant A, Liss Y, Bork K, et al. ALDEN, an algorithm for assessment of drug causality in Stevens-Johnson Syndrome and toxic epidermal necrolysis: comparison with case-control analysis. Clin Pharmacol Ther. 2010; 88: 60-8.

[34] Lazarević VV. Diagnosis, Investigation and Management of Non-immediate (Type IV) Cutaneous Adverse Drug Reactions. Acta Dermatovenerol Croat. 2024; 32: 88-95.

[35] Koo G, Stollings JL, Lindsell C, Dear ML, Kripalani S, Nelson GE, et al. ; Vanderbilt University Medical Center Learning Healthcare System. Low-risk penicillin allergy delabeling through a direct oral challenge in immunocompromised and/or multiple drug allergy labeled patients in a critical care setting. J Allergy Clin Immunol Pract. 2022; 10: 1660-3.e2.

[36] Redmond M, Scherzer R, Hardy C, Macias C, Samora J, Stukus D. In-Office Amoxicillin to Increase Graded-Dose Challenges at Initial Evaluation for Penicillin Allergy. J Allergy Clin Immunol Pract. 2023; 11: 2190-5.